European Journal of Clinical Pharmacology

, Volume 63, Issue 11, pp 1075–1083

Recognition and management of potential drug–drug interactions in patients on internal medicine wards

  • Priska Vonbach
  • André Dubied
  • Jürg H. Beer
  • Stephan Krähenbühl
Pharmacoepidemiology and Prescription



Our aim was to study and possibly improve the clinical management of potential drug–drug interactions (pDDIs) in hospitalized patients by specific interventions.


During the initial period, inpatients on three medical wards were screened for major and moderate pDDIs using the interaction screening program Pharmavista. During the second period, patients at discharge were screened similarly. After assessment of the detected pDDIs for clinical relevance, written recommendations and/or information about the pDDIs were sent to the treating physicians. Feedback from the physicians and implementation of the recommendations were analyzed.


During the initial period, 502 inpatients were exposed to 567 pDDIs, of which 419 (74%) were judged to be clinically relevant. Three hundred and forty-nine substantiated recommendations and 70 simple information leaflets were handed out to the physicians. Eighty percent (278 of 349) of the recommendations were accepted and implemented. During the second period, 792 patients at hospital discharge were exposed to 392 pDDIs, of which 258 (66%) were judged to be clinically relevant. Two hundred and forty-seven substantiated recommendations and 11 simple information leaflets were sent to the physicians. Seventy-three percent (180 of 247) of the recommendations were accepted. At hospital discharge, 47 of 71 interventions recommending checkable medication changes were implemented. One year after hospital discharge, 11 of 13 checked medication changes were still in place.


Clinically relevant pDDIs are common in patients on medical wards, and their management can be influenced by providing substantiated recommendations to physicians. Most changes in medication following such recommendations are still in place 1 year after discharge.


Drug–drug interactions Drug–drug interaction screening program Intervention Medication error Adverse drug reaction 


  1. 1.
    Einarson TR (1993) Drug-related hospital admissions. Ann Pharmacother 27(7–8):832–840PubMedGoogle Scholar
  2. 2.
    Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R et al (1995) Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 274(1):29–34PubMedCrossRefGoogle Scholar
  3. 3.
    Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP (1997) Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277(4):301–306PubMedCrossRefGoogle Scholar
  4. 4.
    Lesar TS, Lomaestro BM, Pohl H (1997) Medication-prescribing errors in a teaching hospital. A 9-year experience. Arch Intern Med 157(14):1569–1576PubMedCrossRefGoogle Scholar
  5. 5.
    Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15):1200–1205PubMedCrossRefGoogle Scholar
  6. 6.
    Fattinger K, Roos M, Vergeres P, Holenstein C, Kind B, Masche U, Stocker DN, Braunschweig S, Kullak-Ublick GA, Galeazzi RL, Follath F, Gasser T, Meier PJ (2000) Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol 49(2):158–167PubMedCrossRefGoogle Scholar
  7. 7.
    van den Bemt PM, Egberts TC, de Jong-van den Berg LT, Brouwers JR (2000) Drug-related problems in hospitalised patients. Drug Saf 22(4):321–333PubMedCrossRefGoogle Scholar
  8. 8.
    Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456):15–19PubMedCrossRefGoogle Scholar
  9. 9.
    Mjorndal T, Boman MD, Hagg S, Backstrom M, Wiholm BE, Wahlin A, Dahlqvist R (2002) Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 11(1):65–72PubMedCrossRefGoogle Scholar
  10. 10.
    Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW (2005) Adverse drug events occurring following hospital discharge. J Gen Intern Med 20(4):317–323PubMedCrossRefGoogle Scholar
  11. 11.
    Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S (2007) Drug-related problems in hospitals : a review of the recent literature. Drug Saf 30(5):379–407PubMedCrossRefGoogle Scholar
  12. 12.
    van der Hooft CS, Sturkenboom MC, van Grootheest K, Kingma HJ, Stricker BH (2006) Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf 29(2):161–168PubMedCrossRefGoogle Scholar
  13. 13.
    Omar MA, Wilson JP (2002) FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 36(2):288–295PubMedCrossRefGoogle Scholar
  14. 14.
    Jankel CA, Fitterman LK (1993) Epidemiology of drug–drug interactions as a cause of hospital admissions. Drug Saf 9(1):51–59PubMedGoogle Scholar
  15. 15.
    Smith L, McGowan L, Moss-Barclay C, Wheater J, Knass D, Chrystyn H (1997) An investigation of hospital generated pharmaceutical care when patients are discharged home from hospital. Br J Clin Pharmacol 44(2):163–165PubMedCrossRefGoogle Scholar
  16. 16.
    Himmel W, Tabache M, Kochen MM (1996) What happens to long-term medication when general practice patients are referred to hospital? Eur J Clin Pharmacol 50(4):253–257PubMedCrossRefGoogle Scholar
  17. 17.
    Cook RI, Render M, Woods DD (2000) Gaps in the continuity of care and progress on patient safety. BMJ 320(7237):791–794PubMedCrossRefGoogle Scholar
  18. 18.
    e-mediat. Pharmavista - information for healthcare professionals. Version February 2005 ed: e-mediat AG, Schönbühl, Switzerland 2005Google Scholar
  19. 19.
    Vonbach P, Dubied A, Krahenbuhl S, Beer JH (2005) Evaluation of drug interaction screening programs. Forum Med Suisse 8S(Suppl 23):P15Google Scholar
  20. 20.
    Stockley IH (2002) Stockley’s drug interactions, 6th edn. The Pharmaceutical Press, London, ChicagoGoogle Scholar
  21. 21.
    Hanlon JT, Weinberger M, Samsa GP, Schmader KE, Uttech KM, Lewis IK, Cowper PA, Landsman PB, Cohen HJ, Feussner JR (1996) A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med 100(4):428–437PubMedCrossRefGoogle Scholar
  22. 22.
    Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, Bates DW (1999) Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 282(3):267–270PubMedCrossRefGoogle Scholar
  23. 23.
    Bond CA, Raehl CL, Franke T (2002) Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy 22(2):134–147PubMedCrossRefGoogle Scholar
  24. 24.
    Dean B, Schachter M, Vincent C, Barber N (2002) Causes of prescribing errors in hospital inpatients: a prospective study. Lancet 359(9315):1373–1378PubMedCrossRefGoogle Scholar
  25. 25.
    Wiltink EH (1998) Medication control in hospitals: a practical approach to the problem of drug–drug interactions. Pharm World Sci 20(4):173–177PubMedCrossRefGoogle Scholar
  26. 26.
    Mannheimer B, Ulfvarson J, Eklof S, Bergqvist M, Andersen-Karlsson E, Pettersson H, von Bahr C (2006) Drug-related problems and pharmacotherapeutic advisory intervention at a medicine clinic. Eur J Clin Pharmacol 62(12):1075–1081PubMedCrossRefGoogle Scholar
  27. 27.
    Chan AL (2005) Pharmacist intervention when interacting drugs are prescribed despite alerts. Am J Health Syst Pharm 62(17):1760–1763PubMedCrossRefGoogle Scholar
  28. 28.
    Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292(21):2585–2590PubMedCrossRefGoogle Scholar
  29. 29.
    Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Hess L, Schlienger RG, Krahenbuhl S (2005) Prevalence of potentially severe drug–drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 28(3):263–275PubMedCrossRefGoogle Scholar
  30. 30.
    Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM (2003) Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis 42(6):1253–1259PubMedCrossRefGoogle Scholar
  31. 31.
    Buurma H, De Smet PA, Egberts AC (2006) Clinical risk management in Dutch community pharmacies : the case of drug–drug interactions. Drug Saf 29(8):723–732PubMedCrossRefGoogle Scholar
  32. 32.
    Kaushal R, Shojania KG, Bates DW (2003) Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. Arch Intern Med 163(12):1409–1416PubMedCrossRefGoogle Scholar
  33. 33.
    Weingart SN, Toth M, Sands DZ, Aronson MD, Davis RB, Phillips RS (2003) Physicians’ decisions to override computerized drug alerts in primary care. Arch Intern Med 163(21):2625–2631PubMedCrossRefGoogle Scholar
  34. 34.
    Payne TH, Nichol WP, Hoey P, Savarino J (2002) Characteristics and override rates of order checks in a practitioner order entry system. Proc AMIA Symp 602–606Google Scholar
  35. 35.
    Shah NR, Seger AC, Seger DL, Fiskio JM, Kuperman GJ, Blumenfeld B, Recklet EG, Bates DW, Gandhi TK (2006) Improving acceptance of computerized prescribing alerts in ambulatory care. J Am Med Inform Assoc 13(1):5–11PubMedCrossRefGoogle Scholar
  36. 36.
    van Roon EN, Flikweert S, le Comte M, Langendijk PN, Kwee-Zuiderwijk WJ, Smits P, Brouwers JR (2005) Clinical relevance of drug–drug interactions : a structured assessment procedure. Drug Saf 28(12):1131–1139PubMedCrossRefGoogle Scholar
  37. 37.
    Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE (2004) Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 76(1):85–96PubMedCrossRefGoogle Scholar
  38. 38.
    Hansten PD, Horn JR, Hazlet TK (2001) ORCA: OpeRational ClassificAtion of drug interactions. J Am Pharm Assoc 41(2):161–165Google Scholar
  39. 39.
    Bobb A, Gleason K, Husch M, Feinglass J, Yarnold PR, Noskin GA (2004) The epidemiology of prescribing errors: the potential impact of computerized prescriber order entry. Arch Intern Med 164(7):785–792PubMedCrossRefGoogle Scholar
  40. 40.
    Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM (2004) Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351(11):1089–1096PubMedCrossRefGoogle Scholar
  41. 41.
    Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA (2003) drug–drug interactions among elderly patients hospitalized for drug toxicity. Jama 289(13):1652–1658PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Priska Vonbach
    • 1
  • André Dubied
    • 1
  • Jürg H. Beer
    • 2
  • Stephan Krähenbühl
    • 3
  1. 1.Hospital PharmacyKantonsspital BadenBadenSwitzerland
  2. 2.Department of MedicineKantonsspital BadenBadenSwitzerland
  3. 3.Clinical Pharmacology & ToxicologyUniversity HospitalBaselSwitzerland

Personalised recommendations